Roche announced Monday that the Food and Drug Administration (FDA), the U.S. health authority, has approved Enspryng for the treatment of optic neuromylitis, a rare autoimmune disease affecting the optic nerve and the spinal cord. .
This monoclonal antibody thus becomes the first drug for subcutaneous injection authorized in the United States for the disease of the optic neuromylitis spectrum, an option which will allow patients to self-inject the treatment every four weeks.
Roche has specified that Enspryng will be marketed in the United States within two weeks.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
–
